The etiology of CP appears to be multifactorial, and prevention requires several approaches depending on the precise etiology. Prevention may be effective where resources exist to diagnose and treat risk factors.
Maternal risk factors such as iodine deficiency, thyroid diseases, and infections should be screened for and treated early. It is important to prevent TORCH (toxoplasmosis, rubella, cytomegalovirus, herpes simplex) infections by vaccination where possible and institute quick treatment when encountered. Unnecessary exposure to antenatal x-rays and unnecessary drug exposure should be avoided. Rh-negative mothers can be treated with immunoglobulins, and infants with jaundice should be treated with phototherapy and transfusions as needed.
Premature births should be prevented, where possible, and aggressive treatment of neonatal complications sought and instigated. Treatments attempt to prevent inflammatory changes that accompany dramatic events such as asphyxia or neonatal stroke in an effort to limit damage to the neural structures.[55]Nelson KB, Chang T. Is cerebral palsy preventable? Curr Op Neurol. 2008 Apr;21(2):129-35.
http://www.ncbi.nlm.nih.gov/pubmed/18317269?tool=bestpractice.com
Magnesium sulfate for fetal neuroprotection
Guidelines recommend that magnesium sulfate should be started within (or as close to as is possible) 4 hours of the expected delivery time of a planned or expected preterm birth.[56]National Institute for Health and Care Excellence (UK). Cerebral palsy in under 25s: assessment and management. January 2017 [internet publication].
https://www.nice.org.uk/guidance/ng62
[57]South Australia Maternal, Neonatal & Gynaecology Community of Practice. Magnesium sulphate for neuroprotection of the fetus in women at risk of preterm birth. 2020 [internet publication].
https://www.sahealth.sa.gov.au/wps/wcm/connect/86f3f2804ee4f45294189dd150ce4f37/Magnesium+Sulphate+for+Neuroprotection+of+the+Fetus_PPG_v4_1.pdf?MOD=AJPERES&CACHEID=ROOTWORKSPACE-86f3f2804ee4f45294189dd150ce4f37-nCfod9V
[58]Magee LA, De Silva DA, Sawchuck D, et al. No. 376 - Magnesium sulphate for fetal neuroprotection. J Obstet Gynaecol Can. 2019 Apr;41(4):505-22.
http://www.ncbi.nlm.nih.gov/pubmed/30879485?tool=bestpractice.com
The Food and Drug Administration recommends against the use of parenteral magnesium sulfate for more than 5 to 7 days to stop preterm labor. Prolonged use may lead to low calcium levels and bone problems in the developing baby or fetus, including osteopenia and fractures.[59]US Food and Drug Administration. Drug safety communications: FDA recommends against prolonged use of magnesium sulfate to stop pre-term labor due to bone changes in exposed babies. May 2013 [internet publication].
https://www.fda.gov/downloads/Drugs/DrugSafety/UCM353335.pdf
There is high-quality evidence to support the use of prenatal neuroprotective magnesium sulfate infusions for women at risk of preterm birth.[60]Committee Opinion No. 455: Magnesium sulfate before anticipated preterm birth for neuroprotection. Obstet Gynecol. 2010 Mar;115(3):669-71.
https://journals.lww.com/greenjournal/citation/2010/03000/committee_opinion_no__455__magnesium_sulfate.33.aspx
http://www.ncbi.nlm.nih.gov/pubmed/20177305?tool=bestpractice.com
[61]Shepherd E, Salam RA, Middleton P, et al. Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev. 2017 Aug 8;(8):CD012077.
http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD012077.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/28786098?tool=bestpractice.com
[62]Doyle LW, Crowther CA, Middleton P, et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004661.
http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD004661.pub3/full
http://www.ncbi.nlm.nih.gov/pubmed/19160238?tool=bestpractice.com
[63]Novak I, Morgan C, Fahey M, et al. State of the Evidence Traffic Lights 2019: systematic review of interventions for preventing and treating children with cerebral palsy. Curr Neurol Neurosci Rep. 2020 Feb 21;20(2):3.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035308
http://www.ncbi.nlm.nih.gov/pubmed/32086598?tool=bestpractice.com
[
]
What are the effects of antenatal and intrapartum interventions for preventing cerebral palsy?/cca.html?targetUrl=https://www.cochranelibrary.com/cca/doi/10.1002/cca.3015/fullShow me the answer
[
]
For women at risk of preterm birth, what are the effects of prenatal magnesium sulfate on maternal outcomes and on infant outcomes extending into childhood?/cca.html?targetUrl=https://www.cochranelibrary.com/cca/doi/10.1002/cca.4497/fullShow me the answer Compared with placebo, magnesium sulfate significantly reduced CP in children born to women at risk of preterm birth (risk ratio 0.68, 95% CI 0.54 to 0.87; five randomized controlled trials; 6145 children).[61]Shepherd E, Salam RA, Middleton P, et al. Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev. 2017 Aug 8;(8):CD012077.
http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD012077.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/28786098?tool=bestpractice.com
[62]Doyle LW, Crowther CA, Middleton P, et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004661.
http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD004661.pub3/full
http://www.ncbi.nlm.nih.gov/pubmed/19160238?tool=bestpractice.com
However, studies included in the meta-analysis assessed the outcome of CP in early childhood (typically ages ≤2 years) when the diagnosis may not always have been certain.
In one placebo-controlled randomized trial, magnesium sulfate given to pregnant women at imminent risk of birth before 30 weeks' gestation was not associated with significant reductions in CP or abnormal motor function in their children when assessed at ages 6 to 11 years.[64]Doyle LW, Anderson PJ, Haslam R, et al; Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Study Group. School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA. 2014 Sep 17;312(11):1105-13.
https://jamanetwork.com/journals/jama/fullarticle/1904828
http://www.ncbi.nlm.nih.gov/pubmed/25226476?tool=bestpractice.com
One Cochrane review concluded that high-quality randomized controlled trials were required to assess the effect of magnesium sulfate for neuroprotection of the term fetus.[65]Nguyen TM, Crowther CA, Wilkinson D, et al. Magnesium sulphate for women at term for neuroprotection of the fetus. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD009395.
http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD009395.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/23450601?tool=bestpractice.com
Corticosteroids
An overview of Cochrane reviews concluded that a single course of maternal corticosteroids (administered to accelerate fetal lung maturation in women at risk for preterm birth) may reduce CP (low-quality evidence), but that repeat doses are unlikely to be more effective than a single course.[63]Novak I, Morgan C, Fahey M, et al. State of the Evidence Traffic Lights 2019: systematic review of interventions for preventing and treating children with cerebral palsy. Curr Neurol Neurosci Rep. 2020 Feb 21;20(2):3.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035308
http://www.ncbi.nlm.nih.gov/pubmed/32086598?tool=bestpractice.com
Postnatal corticosteroids given to preterm babies (at age 8 days or earlier) for preventing chronic lung disease may increase the risk of CP compared with placebo or no treatment.[66]Shepherd E, Salam RA, Middleton P, et al. Neonatal interventions for preventing cerebral palsy: an overview of Cochrane Systematic Reviews. Cochrane Database Syst Rev. 2018 Jun 20;(6):CD012409.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012409.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/29926474?tool=bestpractice.com
Therapeutic hypothermia
When started within 6 hours of birth, therapeutic hypothermia has been found to be neuroprotective.[63]Novak I, Morgan C, Fahey M, et al. State of the Evidence Traffic Lights 2019: systematic review of interventions for preventing and treating children with cerebral palsy. Curr Neurol Neurosci Rep. 2020 Feb 21;20(2):3.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035308
http://www.ncbi.nlm.nih.gov/pubmed/32086598?tool=bestpractice.com
[66]Shepherd E, Salam RA, Middleton P, et al. Neonatal interventions for preventing cerebral palsy: an overview of Cochrane Systematic Reviews. Cochrane Database Syst Rev. 2018 Jun 20;(6):CD012409.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012409.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/29926474?tool=bestpractice.com
[67]Jacobs SE, Berg M, Hunt R, et al. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD003311.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003568
http://www.ncbi.nlm.nih.gov/pubmed/23440789?tool=bestpractice.com
Compared with standard care, therapeutic hypothermia reduced CP among newborns with hypoxic ischemic encephalopathy (risk ratio 0.66, 95% CI 0.54 to 0.82).[66]Shepherd E, Salam RA, Middleton P, et al. Neonatal interventions for preventing cerebral palsy: an overview of Cochrane Systematic Reviews. Cochrane Database Syst Rev. 2018 Jun 20;(6):CD012409.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012409.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/29926474?tool=bestpractice.com
[67]Jacobs SE, Berg M, Hunt R, et al. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD003311.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003568
http://www.ncbi.nlm.nih.gov/pubmed/23440789?tool=bestpractice.com
[
]
What are the benefits and harms of cooling in newborns with hypoxic ischemic encephalopathy?/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.301/fullShow me the answer
Putative neuroprotective interventions
Prophylactic methylxanthines (caffeine) for preterm infants having endotracheal extubation may be associated with a reduction in CP risk (compared with placebo).[63]Novak I, Morgan C, Fahey M, et al. State of the Evidence Traffic Lights 2019: systematic review of interventions for preventing and treating children with cerebral palsy. Curr Neurol Neurosci Rep. 2020 Feb 21;20(2):3.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035308
http://www.ncbi.nlm.nih.gov/pubmed/32086598?tool=bestpractice.com
[66]Shepherd E, Salam RA, Middleton P, et al. Neonatal interventions for preventing cerebral palsy: an overview of Cochrane Systematic Reviews. Cochrane Database Syst Rev. 2018 Jun 20;(6):CD012409.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012409.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/29926474?tool=bestpractice.com
One study reported that recombinant human erythropoietin reduced long-term neurologic disability when given to very premature infants, but other studies showed no clear benefit.[66]Shepherd E, Salam RA, Middleton P, et al. Neonatal interventions for preventing cerebral palsy: an overview of Cochrane Systematic Reviews. Cochrane Database Syst Rev. 2018 Jun 20;(6):CD012409.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012409.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/29926474?tool=bestpractice.com
[68]Song J, Sun H, Xu F, et al. Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Ann Neurol. 2016 Jul;80(1):24-34.
https://onlinelibrary.wiley.com/doi/full/10.1002/ana.24677
http://www.ncbi.nlm.nih.gov/pubmed/27130143?tool=bestpractice.com
Preventive antibiotics (for women in preterm labor when their waters have not broken, and immediate birth for preterm babies with suspected compromise) have been shown to be probably ineffective and could cause harm.[61]Shepherd E, Salam RA, Middleton P, et al. Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev. 2017 Aug 8;(8):CD012077.
http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD012077.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/28786098?tool=bestpractice.com